Literature DB >> 26788589

The emerging roles of liver X receptors and their ligands in cancer.

Chin-Yo Lin1, Lise-Lotte Vedin2, Knut R Steffensen2.   

Abstract

INTRODUCTION: Liver X receptors (LXRs) are nuclear receptors with well-known functions in cholesterol transport, fatty acid and glucose metabolism, and modulation of immune responses. Natural and synthetic ligands have been identified and are under development for the treatment of metabolic and inflammatory conditions and diseases. There is mounting evidence pointing to functional roles for LXRs in a variety of malignancies and the potential therapeutic efficacy of their ligands. AREAS COVERED: This review summarizes the discovery and characterization of LXRs and their ligands, surveys their effects and mechanisms of action in cell-based and animal models of cancer, and proposes the future direction of basic and translational studies of LXRs and their ligands in cancer research and therapeutics. EXPERT OPINION: Targeting LXRs is a promising strategy for cancer treatment, particularly for those cancers which do not have effective treatment options. Key questions remain, however, regarding the specific mechanisms of action, effects on other target cells within the tumor microenvironment, and receptor status in patient populations. Moreover, LXR ligands optimized for disease-specific functions and cancer-related endpoints are currently not available. These issues represent both challenges and significant opportunities for future research and development efforts.

Entities:  

Keywords:  cancer; liver X receptor; nuclear receptor; oxysterol

Mesh:

Substances:

Year:  2015        PMID: 26788589     DOI: 10.1517/14728222.2015.1081169

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  16 in total

Review 1.  LXRα Phosphorylation in Cardiometabolic Disease: Insight From Mouse Models.

Authors:  Maud Voisin; Matthew C Gage; Natalia Becares; Elina Shrestha; Edward A Fisher; Ines Pineda-Torra; Michael J Garabedian
Journal:  Endocrinology       Date:  2020-07-01       Impact factor: 4.736

2.  Liver X receptor agonists exert antitumor effects against hepatocellular carcinoma via inducing REPS2 expression.

Authors:  Xiao-Yu He; Meng-Meng Zhu; Juan Zheng; Cheng-Yi Wang; Xiao-Kang Zhao; Bao-Tong Zhang; Da-Chen Zhou; Shuang Zhang; Xiao-Xiao Yang; Ya-Jun Duan; Ji-Hong Han; Yuan-Li Chen
Journal:  Acta Pharmacol Sin       Date:  2022-08-22       Impact factor: 7.169

3.  Histone variant macroH2A1 rewires carbohydrate and lipid metabolism of hepatocellular carcinoma cells towards cancer stem cells.

Authors:  Oriana Lo Re; Julien Douet; Marcus Buschbeck; Caterina Fusilli; Valerio Pazienza; Concetta Panebianco; Carlo Castruccio Castracani; Tommaso Mazza; Giovanni Li Volti; Manlio Vinciguerra
Journal:  Epigenetics       Date:  2018-09-29       Impact factor: 4.528

Review 4.  Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.

Authors:  Ji Min Oh; Byeong-Cheol Ahn
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

5.  Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment.

Authors:  Haixia Cao; Shaorong Yu; Dan Chen; Changwen Jing; Zhuo Wang; Rong Ma; Siwen Liu; Jie Ni; Jifeng Feng; Jianzhong Wu
Journal:  FEBS Open Bio       Date:  2016-12-20       Impact factor: 2.693

Review 6.  The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease.

Authors:  Michael B Fessler
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

7.  Induction of SOCS3 by liver X receptor suppresses the proliferation of hepatocellular carcinoma cells.

Authors:  Haojun Xiong; Yan Zhang; Shan Chen; Zhenhong Ni; Jintao He; Xinzhe Li; Bo Li; Kai Zhao; Fan Yang; Yijun Zeng; Bingbo Chen; Fengtian He
Journal:  Oncotarget       Date:  2017-07-18

8.  Dendrogenin A drives LXR to trigger lethal autophagy in cancers.

Authors:  Gregory Segala; Marion David; Philippe de Medina; Mathias C Poirot; Nizar Serhan; François Vergez; Aurelie Mougel; Estelle Saland; Kevin Carayon; Julie Leignadier; Nicolas Caron; Maud Voisin; Julia Cherier; Laetitia Ligat; Frederic Lopez; Emmanuel Noguer; Arnaud Rives; Bruno Payré; Talal Al Saati; Antonin Lamaziere; Gaëtan Despres; Jean-Marc Lobaccaro; Silvere Baron; Cecile Demur; Fabienne de Toni; Clément Larrue; Helena Boutzen; Fabienne Thomas; Jean-Emmanuel Sarry; Marie Tosolini; Didier Picard; Michel Record; Christian Récher; Marc Poirot; Sandrine Silvente-Poirot
Journal:  Nat Commun       Date:  2017-12-04       Impact factor: 14.919

9.  What are the characteristics of vitamin D metabolism in opioid dependence? An exploratory longitudinal study in Australian primary care.

Authors:  Albert Stuart Reece; Gary Kenneth Hulse
Journal:  BMJ Open       Date:  2018-01-13       Impact factor: 2.692

10.  A de novo substructure generation algorithm for identifying the privileged chemical fragments of liver X receptorβ agonists.

Authors:  He Peng; Zhihong Liu; Xin Yan; Jian Ren; Jun Xu
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.